LEXINGTON, Mass.--(BUSINESS WIRE)--Critical Therapeutics (Nasdaq: CRTX) today announced the presentation of three posters at the American College of Allergy, Asthma and Immunology (ACAAI) 2006 Annual Meeting in Philadelphia. Two posters highlighted efficacy data for the twice daily, controlled-release formulation of zileuton (zileuton CR). The third poster reviewed data showing zileuton’s impact on inflammation in a preclinical model of asthma. Zileuton CR, an investigational drug, is a 5-lipoxygenase (5-LO) inhibitor designed to block the production of 5-LO, an enzyme responsible for asthma symptoms. The Company submitted its New Drug Application (NDA) for zileuton CR to the U.S. Food and Drug Administration (FDA) on July 31, 2006. The Prescription Drug User Fee Act (PDUFA) date is currently scheduled for May 31, 2007. Pending regulatory approval, the Company expects to launch zileuton CR in the second half of 2007.
